Ajax Therapeutics
About Ajax Therapeutics
Ajax Therapeutics focuses on developing targeted therapies for hematologic cancers, with a particular emphasis on myeloproliferative neoplasms (MPNs). The company uses state-of-the-art computational chemistry and structural biology to discover and optimize therapies that are highly selective for JAK2 and other related targets, aiming to overcome disease persistence and reduce mutant allele burden. Its clinical program centers on a next-generation Type II JAK2 inhibitor, AJ1-11095, in early-phase trials for myelofibrosis, and it highlights a commitment to precision targeting to address significant unmet medical needs in blood cancers. Headquartered in the United States, Ajax communicates an R&D focus on next-generation inhibition strategies and preclinical/clinical data dissemination.
Recent News
Makary Resigns, BMS Bets $15B on China R&D, and Regenxbio Wins Phase 3 in Duchenne – This Week in Biotech #100
Pharma and Biotech M&As 2026 Deal Watcher
Lilly Lands Vaccine Trifecta with 3 New Biotech Buys Valued at up to $3.8B
Eli Lilly Buys Engage Bio for $202M, Adding Non‑Viral DNA Delivery Platform
Eli Lilly to Acquire Ajax Therapeutics for ~$2.3B
Lilly Targets Kidney Disease with Ascidian’s RNA Exon Editors for up to $1.9B
Business Watch: Braskem Gets a New Majority Owner; Lilly Buying Ajax for $2.3 Billion
Top Biotech Deals in April 2026
Eli Lilly to Acquire Three Vaccine Makers for $3.8 Billion, Expanding Preventive Portfolio
Lilly to Acquire Ajax Therapeutics